14
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Prevention of Experimental Cyclosporine Nephrotoxicity by Dietary Supplementation with LSL 90202, a Lysine Salt of Eicosapentaenoic Acid

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cyclosporine (CsA) nephrotoxicity is partially mediated by renal vasoconstriction due to an imbalance between vasodilator and vasoconstrictor eicosanoids. LSL 90202 is a purified lysine salt of eicosapentaenoic acid which is a known inhibitor of renal eicosanoid synthesis. The aim of the present work was to determine if chronic dietary supplementation with LSL 90202 prevented CsA nephrotoxicity and to establish the role of thromboxane and prostacyclin in renal tissue. Thirty-three male Sprague-Dawley rats were divided into 4 groups: group 1, CsA in olive oil (n = 10); group 2, isovolumetric olive oil (n = 7); group 3, CsA in olive oil plus LSL 90202 (n = 8); group 4, isovolumetric olive oil plus LSL 90202 (n = 8). CsA and LSL 90202 were given at 20 mg/kg/day. Weight and creatinine clearance (CrCl) were determined before and on days 14 and 30. On day 30 whole-blood CsA was determined and renal tissue processed for renal malondialdehyde, thromboxane B2 and 6-keto-PGF<sub>1α</sub> measurement and for conventional histology. CrCl was severely reduced in the CsA in olive oil group compared to olive oil and LSL 90202 control groups. On day 30, CrCl in the CsA in olive oil plus LSL 90202 group showed a slight decrease, but the mean CrCl was significantly higher than in the CsA in olive oil group. Trough whole blood CsA levels were not significantly different in both groups given the drug. No morphological differences were found between groups. Renal content of thromboxane B2 and 6-keto-PGF<sub>1α</sub> (the stable metabolites of thromboxane A2 and prostacyclin, respectively) was higher in CsA in olive oil group than in olive oil control group. In contrast, both eicosanoids were similarly low in both groups receiving LSL 90202. The difference between group 1 and group 3 was statistically significant. In summary, our results suggest that LSL 90202 modifies CsA nephrotoxicity and that its benefitial effect may be due to its influence on intrarenal biosynthesis of thomboxane A2 and prostacyclin.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1994
          1994
          17 December 2008
          : 67
          : 1
          : 66-72
          Affiliations
          aServices of Nephrology, bBiochemistry, and cPathology, dUnitat de Recerca Experimental, Hospital of Bellvitge, Hospitalet de Llobregat, ePharmacology Department, Medicine College, University of Barcelona, Spain
          Article
          187890 Nephron 1994;67:66–72
          10.1159/000187890
          8052370
          d91d4d1d-18c9-4ed4-99c8-b303e7f6d6b9
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 08 June 1993
          Page count
          Pages: 7
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          Cyclosporine,Eicosapentaenoic acid,LSL 90202,Nephrotoxicity,Renal thromboxane B2,6-Keto-PGF1α

          Comments

          Comment on this article